GM1 gangliosidosis is a rare lysosomal storage disorder that occurs in all ages. An inherited gene mutation affects an enzyme that helps break down fats and sugars. These molecules build up in the brain and spinal cord, causing seizures, vision loss and other symptoms. Treatments can ease symptoms, but there isn’t a cure.
GM1 gangliosidosis is a rare disease that causes molecules to build up, irreversibly damaging nerve cells in your brain and spinal cord. You inherit a gene change (mutation) from each of your parents that causes this disorder. Symptoms may appear in infancy, childhood or adulthood. It is a type of lysosomal storage disorder. Unfortunately, there isn't a cure.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Lysosomal storage disorders are a type of inherited metabolic disorder that affect how your metabolism works. Your metabolism helps convert food into energy and get rid of toxins. There are about 50 different lysosomal storage diseases, including Tay-Sachs disease.
Lysosomal refers to lysosomes: small components in cells that contain enzymes. These enzymes help your body break down large molecules like fats and sugars. When these large molecules enter cells, the enzymes change them into simpler ones. When you have a lysosomal storage disorder, your enzymes can’t perform this task. As a result, molecules build up, and your body starts to abnormally store them. This is where the term “storage disorder” (or storage disease) originates.
Lysosomal storage disorders like GM1 gangliosidosis are progressive diseases. The symptoms get worse as more molecules accumulate in your body.
GM1 gangliosidosis is a congenital disease, which means the gene change that causes it is present at birth. However, symptoms may not appear until later in life. Healthcare providers classify GM1 gangliosidosis into types based on when symptoms first appear. There’s often an overlap of symptoms and timing.
Types of GM1 gangliosidosis include:
GM1 gangliosidosis is extremely rare. It affects approximately 1 in every 100,000 to 200,000 people worldwide.
A change in the GLB1 gene causes GM1 gangliosidosis. This gene helps make an enzyme called beta-galactosidase found in lysosomes. The enzyme breaks down molecules like GM1 ganglioside, which plays a critical role in how nerve cells function in your brain.
The gene change prevents your body from breaking down GM1 ganglioside. The molecules start to build up in tissues and organs. The disease causes irreversible damage to cells in your nervous system, particularly your brain and spinal cord.
In order to develop GM1 gangliosidosis, you must inherit a changed GLB1 gene from each parent. In this case, your parents are carriers of the gene change, but they don’t actually have the disease. Your healthcare provider may refer to this as an autosomal recessive disorder.
Even when both parents are carriers of the GLB1 gene mutation, their children may or may not be affected. When the disease occurs, it’s usually the same type that has affected past generations.
When both parents have the gene change, each of their children has a:
Any family may have this genetic mutation, but people of Japanese descent are more likely to develop type 3.
Symptoms of GM1 gangliosidosis vary depending on the type. The types share some of the same symptoms.
Signs of infantile (type 1) GM1 gangliosidosis:
Signs of juvenile (type 2) GM1 gangliosidosis:
Signs of adult (type 3) GM1 gangliosidosis:
If this disease runs in your family, a prenatal test can determine whether your unborn baby has the gene change. The mother-to-be may get a genetic amniocentesis or a chorionic villus sampling (CVS) test to look for cells that have the changed gene.
These tests can diagnose the condition in infants to adults:
There isn’t a medication, procedure or cure for GM1 gangliosidosis. Treatments focus on minimizing symptoms unique to the individual to improve quality of life. For instance, a ketogenic diet (keto diet) for epilepsy and anticonvulsant drugs like gabapentin may alleviate seizures.
However, medical researchers are actively looking for new ways to treat and stop the disease. You or your child may be able to participate in a clinical trial to try promising new therapies still in development. These therapies may include:
If you carry the mutated gene that causes GM1 gangliosidosis, a genetic counselor can discuss options for lowering the odds of passing it on to your children. For instance, you may use preimplantation genetic diagnosis (PGD) to identify embryos that don’t carry the mutated gene. Your healthcare provider implants the healthy embryos using in vitro fertilization (IVF). PGD guarantees your child won’t be a carrier or develop the disease.
Symptoms of GM1 gangliosidosis get progressively worse over time. The life expectancy and quality of life for someone with GM1 gangliosidosis varies depending on the type:
Call your healthcare provider if you or your child experiences:
You may want to ask your healthcare provider:
A note from Cleveland Clinic
GM1 gangliosidosis is a rare inherited disease that prevents your body from breaking down fat and sugar molecules. It’s a type of lysosomal storage disorder. As the molecules build up, you experience symptoms like seizures, balance problems and difficulty swallowing. In order to develop this disease, you must inherit a copy of the gene mutation that causes it from both your mother and father. Treatments focus on easing specific symptoms. There isn’t a cure, but there are clinical trials underway for new therapies. Your healthcare provider can discuss ways to lower the chances of passing the gene mutation to future generations.
Last reviewed by a Cleveland Clinic medical professional on 08/29/2022.
Learn more about our editorial process.